Kenvue Stock - CEO transition and strategic review reshape outlook

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 17:52 CET. Details in the imprint.

Kenvue (US49177J1025) has overhauled its top leadership by removing CEO Thibaut Mongon and appointing Kirk Perry, alongside a strategic review of its portfolio, according to recent media reports on the management shake-up and review process. The moves follow pressure from activist investors seeking higher profitability and capital returns.

Leadership change and review

The maker of Tylenol and Listerine removed Thibaut Mongon as CEO and named former Google and Procter & Gamble executive Kirk Perry as interim chief in mid-2025, alongside a strategic portfolio review under activist pressure to improve returns.

According to coverage of the decision, Kenvue is examining options to simplify its brand portfolio, sharpen focus on higher-margin franchises and consider potential divestitures or restructurings to unlock shareholder value.

Long-term strategy under scrutiny

The leadership reset comes less than two years after Johnson & Johnson spun off Kenvue as a standalone consumer health company, placing renewed attention on whether the current brand mix and cost base can support durable mid-single-digit growth with expanding margins.

Analysts and investors are watching whether the new leadership team leans toward incremental cost optimization or a bolder reshaping of the portfolio, including possible exits from slower-growing or lower-margin categories over the next several years.

How the company makes money

Kenvue generates revenue from a broad portfolio of consumer health brands across self-care, skin health and essential health, including over-the-counter medicines such as Tylenol, pain relief and cold remedies, as well as oral care products and everyday skincare lines sold globally through retail and pharmacy channels.

Where the stock trades today

Kenvue shares trade on the New York Stock Exchange under the ticker KVUE; the latest available quote shows the stock at $18.17 as of 06/18/2026, 15:59 Eastern Time.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.